The CDC recommends the vaccine pause while it investigates “serious adverse events,” including neurologic and cardiac events.

The decision follows ongoing investigations into serious adverse events primarily reported in elderly individuals who ...

Both the FDA and EMA have suspended Ixchiq’s use in older adults after post-marketing serious adverse events that include two ...

FDA and CDC recommend halting Ixchiq vaccine use in adults 60 and older after reports of serious adverse events, including ...

Reports of severe adverse events in some people who received the chikungunya vaccine have spurred regulators in Europe and ...

TUESDAY, May 13, 2025 (HealthDay News) — U.S. health officials are telling travelers aged 60 and older to avoid a chikungunya ...

The FDA and CDC recommended a pause for Ixchiq, a chikungunya vaccine, following reports of adverse events in recipients 60 ...

On the heels of similar moves in France and the European Union, U.S. health authorities are calling for a pause in the use of ...

The U.S. government is advising that international travelers age 60 and older not get a chikungunya vaccine as it ...

Centres for Disease Control and Prevention (CDC) has issued an advisory urging American travellers over the age of 60 years ...

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the U.S. Food and Drug Association (FDA) and the U.S. Centers for Disease Control and Prevention (CDC) ...

Adults over the age of 60 are recommended not to get the chikungunya vaccine to prevent the mosquito-borne illness due to two ...